Thrombelastography versus antifactor Xa levels in the assessment of prophylactic-dose enoxaparin in critically ill patients

Journal of Trauma - Injury, Infection and Critical Care

Volumn 66, Issue 6, 2009, Pages 1509-1515

  Van, Philbert Y ^a   Cho, S David ^a   Underwood, Samantha J ^a   Morris, Melanie S ^a   Watters, Jennifer M ^a   Schreiber, Martin A ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Antifactor Xa; Deep venous thrombosis; Enoxaparin; Fibrinolysis; Lowmolecular weight heparin; Thrombelastography

Indexed keywords

BLOOD CLOTTING FACTOR 10A ANTIBODY; ENOXAPARIN; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIBODY BLOOD LEVEL; APACHE; ARTICLE; BLOOD CLOTTING; BODY MASS; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DEEP VEIN THROMBOSIS; FEMALE; HUMAN; HYPERCOAGULABILITY; INJURY SEVERITY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SCREENING; THROMBOELASTOGRAPHY; THROMBOSIS PREVENTION; CHEMOPROPHYLAXIS; COMPARATIVE STUDY; CRITICAL ILLNESS; IMMUNOLOGY; MIDDLE AGED; PREDICTION AND FORECASTING; VEIN THROMBOSIS;

ANTIBODIES; ANTICOAGULANTS; CHEMOPREVENTION; CRITICAL ILLNESS; ENOXAPARIN; FACTOR XA; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; THROMBELASTOGRAPHY; VENOUS THROMBOSIS;

EID: 67749084293     PISSN: 00225282     EISSN: 15298809     Source Type: Journal    
DOI: 10.1097/TA.0b013e3181a51e33     Document Type: Article

References (31)

1. Geerts W, Selby R. Prevention of venous thromboembolism in the ICU. Chest. 2003;124(6 Suppl):357S-363S. (Pubitemid 38005462)
2. Cook DJ, Crowther MA, Meade MO, Douketis J; VTE in the ICU Workshop Participants. Prevalence, incidence, and risk factors for venous thromboembolism in medical-surgical intensive care unit patients. J Crit Care. 2005;20:309-313.
3. Shorr AF, Ramage AS. Enoxaparin for thromboprophylaxis after major trauma: potential cost implications. Crit Care Med. 2001; 29:1659-1665.
4. O'Malley KF, Ross SE. Pulmonary embolism in major trauma patients. J Trauma. 1990;30:748-750. (Pubitemid 20197994)
5. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):338S- 400S.
6. Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A prospective study of venous thromboembolism after major trauma. N Engl J Med. 1994;331:1601-1606. (Pubitemid 24372057)
7. Geerts WH, Jay RM, Code KI, et al. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med. 1996;335:701-707. (Pubitemid 26287356)
8. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of lowmolecular- weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002;162:1729-1735. (Pubitemid 34894802)
9. Lee AY, Levine MN, Baker RI, et al; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146-153.
10. Nurmohamed MT, Verhaeghe R, Haas S, et al. A comparative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery. Am J Surg. 1995;169:567-571.
11. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and lowmolecular- weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119(1 Suppl): 64S-94S. (Pubitemid 32154195)
12. Bara L, Planes A, Samama MM. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and Ddimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery. Br J Haematol. 1999;104:230-240. (Pubitemid 29083328)
13. Linkins LA, Julian JA, Rischke J, Hirsh J, Weitz JI. In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation. Thromb Res. 2002;107:241-244. (Pubitemid 35435383)
14. Boneu B. Low molecular weight heparin therapy: is monitoring needed? Thromb Haemost. 1994;72:330-334. (Pubitemid 24280767)
15. Haas CE, Nelson Jl, Raghavendran K, et al. Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients. J Trauma. 2005;59:1336 -1343; discussion 1343-1344.
16. Brophy DF, Martin EJ, Gehr TW, Best AM, Paul K, Carr ME Jr. Thrombin generation time is a novel parameter for monitoring enoxaparin therapy in patients with end-stage renal disease. J Thromb Haemost. 2006; 4:372-376.
17. Mayr AJ, Dünser M, Jochberger S, et al. Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin. Thromb Res. 2002;105:201-204. (Pubitemid 34260941)
18. Al Dieri R, Alban S, Béguin S, Hemker HC. Fixed dosage of lowmolecular- weight heparins causes large individual variation in coagulability, only partly correlated to body weight. J Thromb Haemost. 2006;4:83-89.
19. Salooja N, Perry DJ. Thrombelastography. Blood Coagul Fibrinolysis. 2001;12:327-337. (Pubitemid 32730491)
20. Nasser NJ, Sarig G, Brenner B, et al. Heparanase neutralizes the anticoagulation properties of heparin and low-molecular-weight heparin. J Thromb Haemost. 2006;4:560-565.
21. Zmuda K, Neofotistos D, Ts'ao CH. Effects of unfractionated heparin, low-molecular-weight heparin, and heparinoid on thromboelastographic assay of blood coagulation. Am J Clin Pathol. 2000;113:725-731. (Pubitemid 33044314)
22. Coppell JA, Thalheimer U, Zambruni A, et al. The effects of unfractionated heparin, low molecular weight heparin and danaparoid on the thromboelastogram (TEG): an in-vitro comparison of standard and heparinase-modified TEGs with conventional coagulation assays. Blood Coagul Fibrinolysis. 2006;17:97-104.
23. Dörffler-Melly J, de Jonge E, Pont AC, et al. Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet. 2002;359:849-850. (Pubitemid 34233758)
24. Priglinger U, Delle Karth G, Geppert A, et al. Prophylactic anticoagulation with enoxaparin: is the subcutaneous route appropriate in the critically ill? Crit Care Med. 2003;31:1405-1409. (Pubitemid 36583851)
25. Brophy DF, Martin EJ, Best AM, Gehr TW, Carr ME. Antifactor Xa activity correlates to thrombin generation time, platelet contractile force and clot elastic modulus following ex vivo enoxaparin exposure in patients with and without renal dysfunction. J Thromb Haemost. 2004;2:1299-1304.
26. Gerotziafas GT, Chakroun T, Samama MM, Elalamy I. In vitro comparison of the effect of fondaparinux and enoxaparin on whole blood tissue factor-triggered thromboelastography profile. Thromb Haemost. 2004;92:1296-1302. (Pubitemid 39642540)
27. Lisman T, Adelmeijer J, Nieuwenhuis HK, de Groot PG. Enhancement of fibrinolytic potential in vitro by anticoagulant drugs targeting activated factor X, but not by those inhibiting thrombin or tissue factor. Blood Coagul Fibrinolysis. 2003;14:557-562. (Pubitemid 37083171)
28. Murata T, Nakashima Y, Yasunaga C, Maeda K, Sueishi K. Extracellular and cell-associated localizations of plasminogen activators and plasminogen activator inhibitor-1 in cultured endothelium. Exp Mol Pathol. 1991;55:105-118.
29. Brohi K, Cohen MJ, Ganter MT, et al. Acute coagulopathy of trauma: hypoperfusion induces systemic anticoagulation and hyperfibrinolysis. J Trauma. 2008;64:1211-1217; discussion 1217. (Pubitemid 351671214)
30. Bajzar L, Jain N, Wang P, Walker JB. Thrombin activatable fibrinolysis inhibitor: not just an inhibitor of fibrinolysis. Crit Care Med. 2004;32(5 Suppl):S320-S324.
31. Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood. 1996;88:2093-2100. (Pubitemid 26307911)